Načítá se...
Biphasic human insulin 30 thrice daily, is it reasonable?
OBJECTIVE: To evaluate the efficacy and safety of thrice daily Biphasic Human Insulin 30 (BHI 30) versus the traditional twice-daily regimen in type 2 diabetes mellitus (T2DM) patients. It’s a cross over single clinical study. Twenty-two diabetic patients who were already using BHI 30 in twice or th...
Uloženo v:
| Vydáno v: | BMC Res Notes |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7247174/ https://ncbi.nlm.nih.gov/pubmed/32448382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-020-05090-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|